STAT

Opinion: 23andMe had devastating news about my health. I wish a person had delivered it

When I decided to do a 23andMe genetic test, I checked all of the boxes to keep my results as secret as possible. Privacy, it turned out, was the least…
Source: ERIC BARADAT/AFP/Getty Images

Last summer, I thought it might be fun to have my DNA analyzed. Two companies, 23andMe and Ancestry.com, had popped up again and again in my social feeds, so I decided to join the party and see if I could blame my penchant for salty food on my genes. And as a journalist, I was just naturally curious.

So like 26 million other people, I ordered a testing kit online, spat into a tube, and sent my saliva off to Silicon Valley. Any concerns I had were around privacy. I checked all of the boxes to keep my results as secret as possible and went back to my normal life.

Privacy, it turned out, was the least of my worries.

I had just gotten home from the gym when I opened the email from 23andMe, saying a report was ready for me to read. That click changed my life forever: To my utter shock, the results showed that I have a mutation in a gene called BRCA1, which puts me at a huge risk of developing breast and ovarian cancer. I broke into tears.

At first, I didn’t believe what I was seeing. My father’s sister died of breast cancer when she was 37, but her mother (my grandmother) that’s still only 2.5% of my tribe.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readChemistry
STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks